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Abstract
Obsessive–compulsive disorder is a prevalent and disabling lifespan disorder. Clomipramine and the
SSRIs have been found to be eﬀective across the range of symptoms, both in acute and longer-term studies.
Meta-analyses have reported a larger treatment eﬀect for clomipramine relative to the SSRIs, but this is
not supported by evidence from head-to-head comparator studies and, based on their superior safety
and tolerability, SSRIs are the preferred option for long-term treatment in most cases. The treatment-eﬀect
is usually gradual and partial, and many patients fail to respond adequately to ﬁrst-line treatment.
Pharmacological options for refractory cases include switching SRI, increasing the dose, or augmenting
with an antipsychotic agent. Novel strategies are under investigation for this highly morbid group. This
paper reviews the key questions related to OCD pharmacotherapy, synthesizing evidence derived from
randomized controlled trials, meta-analyses and consensus guidelines.
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Introduction
Obsessive–compulsive disorder (OCD) is now rec-
ognized to be a common, treatable illness with a
distinctive pathophysiology and pharmacology.
Wide-ranging epidemiological surveys have repeat-
edly demonstrated high lifetime prevalence, amount-
ing to 2–3% of the population worldwide under
DSM-III and DSM-III-R criteria (Robins et al., 1984;
Weissman et al., 1994). However only a fraction of
suﬀerers present for treatment and the diagnosis is
often missed. OCD is somewhat more common in
women than men (ratio 1.5 :1) and the mean age of
onset is reported as 20 yr, with bimodal peaks at
12–14, and 20–22 yr (Rasmussen and Eisen, 1990).
There is a high childhood incidence and, if untreated,
OCD runs a ﬂuctuating, unremitting course with
the greatest prevalence in early-middle adult life. A
substantial lifetime comorbidity with several DSM-IV
Axis I and Axis II disorders have been identiﬁed
(Hollander et al., 1998), including depression which
supervenes in approximately two thirds of cases,
simple phobia (22%), social phobia (18%), eating dis-
order (17%), alcohol dependence (14%), panic dis-
order (12%) and Tourette’s syndrome (7%; Pigott
et al., 1994), and increased rates of suicidal behaviour.
The costs of OCD to society, in terms of individual
suﬀering, diminished human potential and lost rev-
enue, are high (Hollander and Wong, 1998).
The systematic investigation of OCD has depended,
to a large extent, on the introduction of universally
accepted diagnostic criteria and the development
of comprehensive and sensitive rating scales that
measure small changes in symptoms, such as the
6- and 8-item scales (Montgomery and Montgomery,
1980; Thoren et al., 1980 respectively) derived from
the Comprehensive Psychopathological Rating Scale
(CPRS; Asberg et al., 1978) and the Yale–Brown
Obsessive Compulsive Scale (YBOCS; Goodman
et al., 1984). However, in spite of such advances,
OCD remains poorly recognized and under-treated.
Although surveys suggest the time lag between
symptom onset and correct diagnosis is shortening,
patients still wait an average of 17 yr before appro-
priate treatment is initiated (Hollander and Wong,
1998). It is often only when depression supervenes
that OCD suﬀerers present for treatment. At this point
it is vital to the success of clinical intervention that
the OCD is not overlooked.
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This review considers the evidence base for the
pharmacological management of OCD based upon,
wherever possible, randomized controlled trials
(RCTs). Three fundamental clinical issues are ad-
dressed: (1) what are the ﬁrst-line treatments? (2) how
long should treatment continue? and (3) what is the
preferred treatment for those who do not respond to
ﬁrst-line agents? Uncontrolled studies are cited where
systematic data is lacking and meta-analyses are cited
where adequate head-to-head comparator-studies do
not exist. Expert consensus guidelines are considered
and practical recommendations made for the clinical
setting. A systematic search of electronic databases
[EMBase (1974–date), MEDLINE (1966–date), PsychInfo
(1987–date)] was run using combinations of the terms
obsessive compulsive (randomised or control$ or clinical
trial$ or placebo$ or blind$) and (systematic or review$ or
meta-analysis), as well as individual drug names. This
was complemented by consulting with colleagues
in the ﬁeld and reviewing recent data presented at
international, peer-reviewed symposia. Most pub-
lished studies have investigated acute treatment of
OCD, with a shortage of long-term and relapse-
prevention data. The results from a growing number
of studies on children suggest they respond similarly
to adults. There is a regrettable shortage of data on
pharmacotherapy of OCD in the elderly.
The weight of evidence shows that OCD responds
preferentially to drugs which powerfully inhibit the
synaptic reuptake of serotonin, i.e. clomipramine and
selective serotonin reuptake inhibitors (SSRIs). Drugs
lacking potent SRI actions have not been eﬀective
in controlled studies. This selective pharmacological
response has generated hypotheses about the role
of serotonin in the aetiology of OCD but, so far, no
unifying theory has emerged and the mechanisms by
which SSRIs exert anti-obsessional beneﬁts remain
poorly understood (Fineberg et al., 1997). It is widely
believed that OCD encompasses a heterogenous group
of illnesses, and that other neurotransmitters are
involved in its pathophysiology.
First-line treatments for OCD
Clomipramine
The ﬁrst uncontrolled case series showing successful
treatment with clomipramine appeared in the 1960s
(Fernandez and Lopez-Ibor, 1967; Reynghe de Voxrie,
1968) and, by 1990, a collection of double-blind,
placebo-controlled trials demonstrated conclusively
that clomipramine is eﬃcacious in OCD, both in the
presence (Flament et al., 1985; Insel et al., 1983; Jenike
et al., 1989; Marks et al., 1980; Mavissakalian et al.,
1985; Thoren et al., 1980) and absence (Marks et al.,
1988; de Veaugh-Geiss et al., 1989; Katz et al., 1990) of
comorbid depression.
Clomipramine in OCD without depression
Early reports suggested that clomipramine may exert
beneﬁt on obsessional symptoms within depression,
and it was unclear if this was an antidepressant eﬀect,
or a more speciﬁc eﬀect on OCD. The ﬁrst study of
‘pure’ OCD patients (Montgomery, 1980) employed
a cross-over design with randomized allocation to
4-wk treatment, and a low ﬁxed daily dose (75 mg) to
protect blinding. Early onset of action was detected
on the 6-item CPRS-OC scale, with signiﬁcant ad-
vantages over placebo at 1, 3, 4 wk in the group com-
parison, and 2, 3, 4 wk in the cross-over analysis,
despite only 14 patients taking part. This ﬁnding was
replicated by Marks et al. (1988), who reported eﬃcacy
over concurrent exposure therapy and placebo, and
by Greist et al. (1990), who demonstrated clear eﬃ-
cacy using only 32 cases. Two multicentre studies of
clomipramine, comprising 238 and 263 cases respect-
ively, and where concomitant depression was ex-
cluded, have been published (see de Veaugh Geiss
et al., 1989; and subsequently the Clomipramine
Collaborative Study Group, 1991). Placebo response
did not exceed 5% reduction in YBOCS total over
10 wk, with signiﬁcant diﬀerences emerging for
clomipramine groups at weeks 1–2. The beneﬁts of
clomipramine, given in ﬂexible doses up to 300 mg/d,
increased slowly and gradually after 1 wk of treatment
up to the 10-wk end-point. The resulting 38% and 44%
(respective) improvements in baseline OC ratings
represented substantial improvement in emotional
and social well-being. Another 10-wk study by Katz
et al. (1990) stratiﬁed patients by the Hamilton
Depression Scale (Hamilton, 1960) scores. In the non-
depressed subgroup, 134 patients improved signiﬁ-
cantly on the National Institute of Mental Health
Global Obsessive Compulsive Scale (NIMH-OC) (Insel
et al., 1983), nearing a 40% reduction of baseline
score (cf. 129 on placebo who remained essentially
unchanged).
Clomipramine in OCD with depression
Eight placebo-controlled studies have investigated
clomipramine in OCD with comorbid depression. A
5-wk study by Thoren et al. (1980) comparing clomi-
pramine to nortriptyline and placebo, showed sig-
niﬁcant improvement on the CPRS-OC scale for
clomipramine over nortriptyline and placebo. In Insel
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et al.’s (1983) cross-over study (n=12), clomipramine
was superior to clorgyline and placebo at 4 and 6 wk.
Moreover, Marks et al. (1980), showed signiﬁcance
at 4 wk for clomipramine in 40 ritualizers although
these ﬁndings relied on self-rated instruments. Further
small studies by Mavissakalian et al. (1985) and Jenike
et al. (1989) also showed signiﬁcance for clomipramine
(100–300 mg) over placebo.
The controlled study by Flament et al. (1985) was
the ﬁrst to demonstrate eﬃcacy of a pharmacological
treatment in childhood OCD. Nineteen children with
primary OCD, aged 6–18 yr entered the 5-wk cross-
over study. A signiﬁcant improvement in obsessional
scores was seen for clomipramine (mean dose
141 mg/d), and this was irrespective of baseline
depression. Signiﬁcant post-baseline improvements
were also observed in the placebo group, suggesting
that children may be susceptible to non-speciﬁc
treatment eﬀects. However, a positive study by de
Veaugh-Geiss et al. (1992) on children and adolescents
reported only an 8% improvement in the placebo
group (n=29) at the 8-wk end-point, compared to 37%
on clomipramine (n=31), with signiﬁcant diﬀerences
evident from 3 wk.
Most of the above studies are small by today’s
standards but the pattern of results is highly consist-
ent. Such consistency is rare in psychopharmacological
research and, together, the results oﬀer unequivocal
support for the eﬃcacy of clomipramine in OCD. They
also reﬂect the special qualities of patients under in-
vestigation at that time. Most had long histories of
stable, severe, untreated illness with few treatment-
refractory cases. The studies’ power also depended
on low placebo-response rates and these distinguish
OCD from depression and other anxiety disorders
where placebo-response rates are higher.
SRIs compared to other antidepressants lacking
strong serotonergic activity
Clomipramine is distinguished from other tricyclics
by its more powerful SRI activity, although its eﬀects
are not exclusively serotonergic. In the ﬁrst cross-
over study comparing clomipramine with the nor-
adrenergic tricyclic desipramine (Insel et al., 1985) the
response to desipramine was indistinguishable from
placebo, whereas clomipramine was superior. Failure
of desipramine relative to clomipramine was seen
more clearly in two cross-over studies in children
(Leonard et al., 1988, 1991), and in later comparisons
with SSRIs such as ﬂuvoxamine (Goodman et al., 1990)
and sertraline (Hoehn-Saric et al., 2000). Likewise, in
studies comparing clomipramine with imipramine,
the former was superior at 6 and 12 wk (Volavka et al.,
1985). Antidepressant responses were reported in
imipramine-treated patients (Foa et al., 1987), but
while clomipramine exerted anti-obsessional beneﬁts,
imipramine did not. In a small, three-way study by
Thoren et al. (1980), clomipramine was superior to
placebo but nortriptyline was not ; and in a small
study by Ananth et al. (1981) there was a signiﬁcant
advantage for clomipramine but not amitriptyline,
The small placebo-controlled cross-over study by
Insel et al. (1983) found clomipramine to be superior
to clorgyline in 13 patients. And although the study
by Vallejo et al. (1992) was probably too small to dis-
criminate between phenelzine and clomipramine,
Jenike et al. (1997) demonstrated a signiﬁcant advan-
tage for ﬂuoxetine over phenelzine, the latter being
indistinguishable from placebo. No study to date has
demonstrated a convincing advantage for a mono-
amine oxidase inhibitor (MAOI) over placebo in OCD.
In some studies, comparator agents may have
shown some anti-obsessional beneﬁt, but the eﬀect is
consistently weaker than that of SRIs. Demonstrating
a signiﬁcant diﬀerence between active treatments
usually requires a large sample size, so the fact that
several small studies show superiority for SRIs
strongly suggests that non-SRIs have little, if any,
eﬃcacy in OCD.
SSRIs
Although clomipramine is a powerful SRI, it has an
active metabolite with strong noradrenergic proper-
ties. That the more highly selective SSRIs are also
beneﬁcial, showing a similar slow, incremental eﬀect,
suggests their anti-obsessional actions are related to
this pharmacological property. Early promising re-
ports suggesting eﬃcacy for zimelidine were curtailed
by the withdrawal of the drug for safety reasons.
Placebo-controlled studies of ﬂuvoxamine
Perse et al. (1987) reported a double-blind cross-over
study of ﬂuvoxamine in 20 patients. Eﬃcacy was evi-
dent after 8 wk, based on 16 completers. Fluvoxamine
also showed superiority over placebo in the 8- and
24-wk analysis by Cottraux et al. (1990), in spite of
concurrent exposure therapy in the placebo group,
thereby emphasizing the strength of the drug eﬀect
relative to psychotherapy. The study has been criti-
cized for not including an intent-to-treat (ITT) analy-
sis and for relying on behavioural ratings for the
OCD. Goodman et al. (1989) demonstrated similar
response proﬁles in depressed and non-depressed
OCD patients with signiﬁcant placebo-referenced
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improvement on the YBOCS from week 2 onwards.
Similar results were reported by Jenike et al. (1990a),
although signiﬁcant diﬀerences appeared only at week
10. The multi-centre study by Goodman et al. (1996),
looking at two groups of 78 patients receiving either
10 wk of ﬂuvoxamine (100–300 mg) or placebo, con-
ﬁrmed superiority for ﬂuvoxamine on all outcome
measures from week 4 onwards. Obsessions and
compulsions both improved with a possible earlier
beneﬁt for obsessions. Only 10 cases discontinued be-
cause of side-eﬀects.
Another multicentre study by Hollander et al.
(2003a) compared 127 patients on ﬂexible, once-daily
doses of controlled-release (CR) ﬂuvoxamine (100–
300 mg), with 126 on placebo. Fluvoxamine CR was
superior in decreasing YBOCS scores from as early
as week 2. By the 12-wk end-point ﬂuvoxamine CR-
treated individuals showed a 32% improvement, com-
pared to 21% on placebo, with signiﬁcantly greater
improvements on Clinical Global Impression–Severity
(CGI-S), Clinical Global Impression–Improvement
(CGI-I) and responder analyses. Remission was de-
ﬁned as either a YBOCS total score of <16, or a sub-
score of <8, and remission rates for ﬂuvoxamine CR
were 44% and 18% respectively. In the ﬂuvoxamine-
treated group, 19% (cf. 6% placebo) withdrew early
through adverse eﬀects (mainly nausea, insomnia,
somnolence, dizziness and diarrhoea).
Riddle et al. (2001) reported the ﬁrst RCT of
ﬂuvoxamine (50–200 mg) in 120 children aged 8–
17 yr. Improvement, on the Children’s Yale–Brown
Obsessive–Compulsive Scale (C-YBOCS), was su-
perior to placebo from weeks 1–6 and at the 10-wk
end-point. Only three patients on ﬂuvoxamine and
one on placebo withdrew through adverse eﬀects. This
ﬁnding supports the rapid eﬃcacy and tolerability of
ﬂuvoxamine in childhood OCD.
Placebo-controlled studies of sertraline
Jenike et al. (1990b) found no group diﬀerences in
a study comparing sertraline (n=10) and placebo
(n=9), although this study was arguably under-
powered. Chouinard et al. (1990) demonstrated
superiority for ﬂexible doses of sertraline (50–200 mg)
on the YBOCS and NIMH-Global OC scale, but not
on the Maudsley Obsessive–Compulsive Inventory
(Hodgson and Rachman, 1977), suggesting that the
latter may lack sensitivity for monitoring clinical
change. Kronig et al. (1999) replicated this work in a
larger sample, demonstrating superiority for sertraline
(50–200 mg, n=86) over placebo (n=81) as early as
3 wk. Ten per cent of the sertraline group and 5% of
the placebo group discontinued because of side-
eﬀects. The subsequent ﬁxed-dose study by Greist
et al. (1995a), which was hampered by a strong
placebo response, showed eﬃcacy on the YBOCS
for pooled sertraline (50–200 mg, n=240) at week 2
onwards compared to placebo (n=84). However, at
the 12-wk end-point, almost as many in the placebo
group (30%) were much or very much improved
compared to those on sertraline (39%). March et al.
(1998) evaluated the eﬃcacy of sertraline, titrated up
to 200 mg, in a cohort of 107 children and 80 ado-
lescents, ﬁnding a signiﬁcant advantage on the C-
YBOCS over placebo as early as 3 wk. Insomnia,
nausea, agitation and tremor were over-represented
in the drug-treated condition and 13% of sertraline
patients discontinued early because of adverse eﬀects
(cf. 3% placebo). Cardiovascular parameters were
systematically monitored and showed no clinically
meaningful abnormalities, suggesting that sertraline
is safe up to doses of 200 mg in children (Wilens
et al., 1999).
Placebo-controlled studies of ﬂuoxetine
Fluoxetine has also been extensively investigated in
OCD. Twomulticentre studies beneﬁted from a design
that allowed comparison of diﬀerent ﬁxed doses. In
the 8-wk study by Montgomery et al. (1993), the 20-mg
dose (n=52) fared no better than placebo (n=56),
while the 40-mg dose (n=52) was superior on the
responder analysis and the 60-mg dose (n=54)
superior both on reduction of YBOCS scores and
responder rate. Side-eﬀects were low and <6% with-
drew early because of them. In the larger, longer
study by Tollefson et al. (1994), all ﬁxed doses of
ﬂuoxetine emerged as superior to placebo by the
13-wk end-point, but there was a trend towards
superiority for the 60-mg dose on the YBOCS analysis.
Side-eﬀects on ﬂuoxetine included nausea, dry mouth,
tremor and sexual problems. A meta-analysis of
separate study data showed no association between
ﬂuoxetine and suicidality in OCD (Beasley et al., 1992).
The placebo-controlled study by Jenike et al. (1997)
investigated doses of ﬂuoxetine up to 80 mg, and
included a comparison with the MAOI phenelzine.
Fluoxetine (n=23) was superior to placebo (n=21)
and phenelzine (n=20), which did not diﬀerentiate
from placebo.
Three studies have looked at ﬂuoxetine in child-
hood OCD, all showing some level of superiority over
placebo. Riddle et al.’s (1992) cross-over study on
14 children used ﬁxed doses of 20 mg. A signiﬁcant
advantage was observed on the CGI but not C-YBOCS,
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which showed a 44% improvement after 8-wk treat-
ment, compared to 27% on placebo. Behavioural acti-
vation occurred as an adverse eﬀect in a few children,
and one left the study early because of suicidal
ideation. The authors considered these side-eﬀects to
be dose-related, advocating initiating treatment at
lower doses. Geller et al. (2001) took a larger cohort,
titrating doses upwards from 10 to 60 mg over 13 wk,
according to clinical response. Fluoxetine was superior
to placebo on the C-YBOCS from week 6 and was well
tolerated across all doses, with similar drop-out rates
from adverse events on drug (8.5%) and placebo.
Leibowitz et al. (2002) extended the dose range to
80 mg after the ﬁrst 6 wk in a trial spanning 7 yr. After
8 wk, responders could continue double-blind treat-
ment for a further 8 wk. Fluoxetine’s eﬀects were
slow to develop, and superiority over placebo did
not emerge until after 8 wk. No patient withdrew be-
cause of adverse eﬀects.
Placebo-controlled studies of paroxetine
Positive results from a ﬁxed-dose study reported in
poster form by Wheadon et al. (1993) were conﬁrmed
in a multinational study by Zohar and Judge (1996),
which included clomipramine as a comparator agent.
Paroxetine, given in doses up to 60 mg (n=201), was
signiﬁcantly more eﬀective than placebo (n=99) on all
a-priori eﬃcacy measures, and of comparable eﬃcacy
to clomipramine (50–250 mg, n=99). Only 9% of
paroxetine-treated patients withdrew because of side-
eﬀects (mainly asthenia, headache, dry mouth and
nausea) compared to 6% given placebo. In a large trial
of 348 OCD patients, Hollander et al. (2003b) tested
paroxetine in ﬁxed doses (20, 40, 60 mg) with placebo.
Respective YBOCS score reductions were 16, 25, 29
and 13% in the acute phase of the study. Both higher
doses were signiﬁcantly diﬀerent from placebo by
week 6 and from the 20-mg dose by week 3. Paroxetine
was well tolerated at all doses.
Placebo-controlled studies of citalopram
The multinational placebo-controlled study by
Montgomery et al. (2001) showed eﬃcacy for ﬁxed
doses of 20 mg (n=102), 40 mg (n=98) and 60 mg
citalopram (n=100) compared to placebo (n=101). A
signiﬁcant reduction in baseline YBOCS score was
seen from week 3 for the 60-mg group, and from
weeks 7–12 for other doses. Citalopram was well
tolerated (4% withdrew through adverse eﬀects;
mainly nausea, headache, fatigue, insomnia) and
improved psychosocial disability on the Sheehan
Disability Scale (Sheehan et al., 1996). To date, there
are no studies relating to the active s-isomer, escitalo-
pram in OCD.
Changes in study populations have aﬀected
treatment studies
The data on SSRIs provides conclusive evidence of
eﬃcacy in OCD. The success of clomipramine and
SSRIs has led to their rapid acceptance as ﬁrst-line
treatments, and it is increasingly diﬃcult for specialist
research centres to recruit patients who are not already
receiving one of these pharmacotherapies. This has
compromised the recruitment of treatment-naı¨ve
patients in more recent studies of SSRIs, where greater
numbers of treatment-refractory individuals have
been included. Moreover, exclusion of comorbid de-
pression has reduced the numbers of severely ill in-
dividuals at baseline. Accordingly, the magnitude of
the observed treatment eﬀect has diminished from
40–50% average reduction in baseline scores in the
clomipramine studies, to around 30% in the later
SSRI studies. Between 32% and 65% of the SSRI-
treated study participants showed a clinically mean-
ingful improvement using the various recognized
criteria for clinical response. Table 1 summarizes the
rates of clinical response in those studies that report
them. Furthermore, increased placebo-response rates,
in some cases exceeding 20% improvement in baseline
scores, have also been observed in more recent
studies, probably resulting from inclusion of milder,
atypical cases, some of whom undergo spontaneous
remission. The rise in the placebo response rate
cautions against drawing conclusions about eﬃcacy
from open, naturalistic reporting, and emphasizes
the importance of controlled investigation. Finally,
the application of increasingly stringent inclusion
criteria in recent studies, often driven by requirements
of regulatory authorities, may well contribute to the
changing pattern of response rates, since treatment
groups are less heterogeneous. By contrast, response
rates in general psychiatry clinics are probably closer
to the original clomipramine results. The net eﬀect of
these changes has been to reduce the statistical power
of the studies, so that larger numbers are now needed
to test the eﬃcacy of new treatments. Meta-analyses
of existing studies can, to some extent, compensate
by pooling data, but if they fail to take these changes
into account they may be misleading.
Meta-analyses of SRIs in OCD
Meta-analyses combine data from separate studies
using speciﬁc rules and provide a more objective and
quantiﬁable measures of treatment-eﬀect size than
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narrative reviews. However, problems may arise in
controlling for between-study diﬀerences such as
dose, duration, blindness, method of assessment and
population diﬀerences, so results must be viewed
cautiously (Pigott and Seay, 1999). In short, meta-
analyses cannot substitute for high-quality head-to-
head comparator trials.
Meta-analyses of existing OCD studies all suggest
superior eﬃcacy for clomipramine over SSRIs. An
analysis by Jenike et al. (1990a) of their work on SSRIs
showed that eﬃcacy correlated negatively with sero-
tonin selectivity. Stein et al. (1995) examined eﬀect
sizes for studies that employed validated rating
scales and were of at least 6 wk duration. However,
although the eﬀect size for clomipramine was larger
than that of comparators, several methodological
and statistical shortcomings were acknowledged,
which limit the conclusions drawn. Piccinelli et al.’s
(1995) meta-analysis related exclusively to double-
blind RCTs of clomipramine and SSRIs, using YBOCS
or NIMH-OC scales. All treatments were signiﬁcantly
superior to placebo, but clomipramine was associated
with signiﬁcantly greater mean YBOCS reduction
(61%) compared to ﬂuoxetine (28.5%), ﬂuvoxamine
(28%), and sertraline (22%) with no signiﬁcant diﬀer-
ence between individual SSRIs. The authors con-
cluded that large-scale controlled comparator studies
are needed to draw ﬁrmer conclusions about relative
eﬃcacy. Greist et al. (1995c) reported on data from
four multi-centre, placebo-controlled studies of
clomipramine, ﬂuoxetine, ﬂuvoxamine and sertraline.
Clomipramine was signiﬁcantly more eﬀective than
SSRIs, which did not diﬀer in calculated eﬀect size
using the YBOCS. Whereas drop-out rates associated
with adverse eﬀects were similar across all groups
(8, 12, 15 and 10% respectively), withdrawal from all
causes was signiﬁcantly lower in the clomipramine
group.
Abramowitz (1997) investigated eﬀect sizes of SRIs
and psychological interventions in RCT data. Using
clinician ratings, clomipramine was again superior to
ﬂuvoxamine, ﬂuoxetine and sertraline (in decreasing
order), and side-eﬀect contrast was signiﬁcantly corre-
lated with eﬀect size. Abramowitz suggested the ap-
parent supremacy of clomipramine may, in part, be
caused by unblinding because it has more noticeable
Table 1. Rates of clinical response in placebo-controlled studies of SSRIs for patients with OCD
Study
Deﬁnition of clinical response
Drug
(duration, wk)
Much or very
much improved
on CGI-I
(Criterion A)
>25% improved
on baseline YBOCS
(Criterion B)
>35%
improved
on baseline
YBOCS
Criteria
A & B
Goodman et al. (1989) 9/21 Fluvoxamine (8)
Goodman et al. (1996) 33.3% Fluvoxamine (10)
Hollander et al. (2003a) 34% from graph 63% 45% Fluvoxamine CR (12)
Riddle et al. (2001) 42% (C-YBOCS) Fluvoxamine (10)
Kronig et al. (1999) 41% Sertraline (12)
Greist et al. (1995a) 38.9% Sertraline (12)
March et al. (1998) 42% Sertraline (12)
Montgomery et al. (1993) 36% Fluoxetine 20 mg (8)
48% Fluoxetine 40 mg (8)
47% Fluoxetine 60 mg (8)
Tollefson et al. (1994) 32% Fluoxetine 20 mg (13)
34% Fluoxetine 40 mg (13)
35% Fluoxetine 60 mg (13)
Geller et al. (2001) 55% Fluoxetine (13)
Leibowitz et al. (2002) 57% Fluoxetine (16)
Zohar and Judge (1996) 55.1% Paroxetine (12)
55.3% Clomipramine (12)
Montgomery et al. (2001) 57.4% Citalopram 20 mg (12)
52% Citalopram 40 mg (12)
65% Citalopram 60 mg (12)
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side-eﬀects. Kobak et al. (1998) extended the pro-
cedure to look at all available studies relating to SRIs
and exposure therapy, regardless of publication
mode and methodology. Data were analysed before
and after attempts to control for methodological vari-
ables, such as year of publication and experimental
design. The results were consistent with previous
meta-analyses, inasmuch as clomipramine had the
largest eﬀect size compared to all the SSRIs apart from
ﬂuoxetine. However, after attempts to control for
methodological variables, clomipramine was not
signiﬁcantly more eﬀective than ﬂuoxetine or ﬂuvox-
amine, but was still superior to other SSRIs. In their
analysis of head-to-head comparisons, however, there
was no signiﬁcant diﬀerence between SRIs. The
authors remarked on the consistency with which
meta-analyses had favoured clomipramine over more
selective SRIs. In spite of its less favourable side-eﬀect
proﬁle, the drop-out rate for clomipramine was no
diﬀerent from the other SRIs. As predicted, year of
publication was negatively correlated with treatment
eﬀect-size. These authors also postulated several
additional biases in favour of clomipramine; for ex-
ample, patients may have been more willing to con-
tinue on clomipramine, in spite of side-eﬀects, because
they inferred they were receiving the active drug,
particularly when no other known alternatives were
available. The unblinding eﬀect may also have biased
patients’ and clinicians’ assessment of improvement.
This paper also acknowledged that its ﬁndings were
not supported by the evidence from head-to-head
trials.
Ackerman and Greenland’s (2002) meta-analysis
attempted to quantify characteristics of published
trials that might account for diﬀerences in eﬀect size.
Although they used diﬀerent techniques, their ﬁnd-
ings broadly agreed with previous analyses. The con-
siderable heterogeneity across studies appeared to be
associated with factors such as year of publication,
length of single-blind pre-randomization period,
length of trial and severity of OCD, and conﬁrmed the
recent rise in placebo-response rates. They concluded
that the superiority of clomipramine in placebo-
controlled trials persisted after controlling for these
factors, but that there was no diﬀerence in studies
comparing clomipramine directly with SSRIs.
Geller et al. (2003a) performed the ﬁrst meta-
analysis on pharmacotherapy for childhood OCD.
Twelve trials were considered and the results were
consistent with the adult literature, showing modest
but signiﬁcant advantages for all SRIs over placebo,
and superiority for clomipramine over SSRIs. SSRIs
were more or less comparable and the ﬁndings were
not dependent on publication date or placebo-
response rate. The authors noted an absence of head-
to-head studies and recommended that clomipramine
should not generally be used ﬁrst-line in children
because of its side-eﬀect proﬁle.
Direct comparison of SRIs in OCD
Thus far, only two controlled studies have compared
the relative eﬃcacy of diﬀerent SSRIs, and the results
are inconclusive. The single-blind study by Mundo
et al. (1997a) that failed to detect diﬀerences between
ﬂuvoxamine, paroxetine and citalopram, was un-
doubtedly underpowered with only 10 patients per
group. Bergeron et al. (2001) compared 77 patients on
sertraline with 73 on ﬂuoxetine, under double-blind
conditions. At the 24-wk end-point, no signiﬁcant
diﬀerence was seen on primary eﬃcacy measures,
but there was a non-signiﬁcant trend toward an earlier
eﬀect in the sertraline group, and a higher number
of sertraline patients reached remission, deﬁned as a
CGI-I score off2 and a YBOCS score off11. In con-
junction with meta-analysis data, these results do
not support the superior eﬃcacy of any one SSRI.
The selection of a particular compound should,
therefore, take account of other factors, such as poss-
ible interactions with other drugs being prescribed.
In this respect, ﬂuoxetine, paroxetine and to a much
lesser extent sertraline, inhibit the P450 isoenzyme
CYP2D6 which metabolizes tricyclic antidepressants,
antipsychotics, anti-arrythmics and beta-blockers,
whereas ﬂuvoxamine inhibits both CYP1A2 and
CYP3A4, which eliminate warfarin, tricyclics, benzo-
diazepines and some anti-arrhythmics. Citalopram is
relatively free from hepatic interactions. Fluoxetine
has a long half-life, and has fewer discontinuation
eﬀects, which can be advantageous for patients who
forget to take their medication.
Whereas meta-analyses consistently report a
smaller eﬀect size for SSRIs relative to clomipramine,
many head-to-head studies demonstrate equivalent
eﬃcacy (Table 2). While many of these were under-
powered (Montgomery et al., 1990), the trial by
Bisserbe et al. (1997) was large enough to detect a
signiﬁcant advantage for sertraline. However the
advantage, apparent for certain measures in the ITT
analysis, was not clear-cut. Another smaller study
found an advantage for clomipramine over ﬂuoxetine
(40 mg) on secondary outcome measures (Lopez-Ibor
et al., 1996). The larger study ﬁrst presented by
Rouillon (1998; see also Mundo et al., 2001) showed
equivalent eﬃcacy for clomipramine and SSRI on
all visits and measures. In the comparator study by
Evidence-based pharmacological treatments for OCD 113
Zohar and Judge (1996) paroxetine and clomipramine
showed similar placebo-referenced eﬃcacy at weeks
6, 8 and 12. Paroxetine was superior to placebo on
depression ratings whereas clomipramine was not.
Response was deﬁned as 25% or more improvement
in baseline YBOCS scores and at end-point, 55% of
both paroxetine- and clomipramine-treated patients
met this criterion, compared to 35% in the placebo
group.
Improved tolerability favours SSRIs
Altogether, the evidence does not appear strong
enough to support superior eﬃcacy of clomipramine
over SSRIs. In the face of equivalence, choice of
SRI depends greatly on the side-eﬀect proﬁle of the
compound. An important advantage of the SSRIs,
compared to clomipramine, lies in their improved
acceptability and tolerability (Table 2). In the com-
parator study of Zohar and Judge (1996), the drop-out
rate from adverse eﬀects on clomipramine (approx.
17%) was consistently higher than for paroxetine
(9%), and Rouillon (1998) reported that clomi-
pramine was associated with signiﬁcantly more early
withdrawals associated with side-eﬀects than ﬂuvox-
amine. Moreover, in Bisserbe et al.’s (1997) ITT analy-
sis, it was concluded that superior tolerability of
sertraline over clomipramine explained its greater
beneﬁt.
The risk of dangerous side-eﬀects such as con-
vulsions (occurring in up to 2% on clomipramine,
compared to 0.1–0.5% on high-dose SSRIs), cardio-
toxicity and cognitive impairment is substantially
lower with SSRIs. Clomipramine shares anticholiner-
gic side-eﬀects associated with tricyclics including dry
mouth, constipation and blurred vision, and is lethal
in overdose. All SRIs are associated with impaired
sexual performance but clomipramine (up to 80%
cases, Monteiro et al., 1987) appears more problematic
than SSRIs (up to 30% cases). SSRIs are responsible for
more asthenia, insomnia, and nausea. Maina et al.
(2003a) reported clinically relevant weight gain in
approx. 14.5% cases (mainly females) over 30 months
of open SRI monotherapy, with clomipramine
Table 2. Controlled studies comparing SSRIs with clomipramine (CMI)
Drug and study n Design
Outcome
Eﬃcacy Tolerability
Fluoxetine (FLX)
Pigott et al. (1990) 11 CMI (50–250 mg) vs. FLX CMI=FLX FLX>CMI
(20–80 mg) CMI=FLX on
primary criterion
Lopez-Ibor et al. (1996) 30 vs. 24 CMI (150 mg) vs. FLX (40 mg) CMI>FLX on
other criteria
FLX=CMI
Fluvoxamine (FLV)
Smeraldi et al. (1992) 10 CMI (200 mg) vs. FLV (200 mg) CMI=FLV FLV=CMI
Freeman et al. (1994) 30 vs. 34 CMI (150–250 mg) vs. FLV CMI=FLV FLV>CMI (on
(150–250 mg) severe eﬀects)
Koran et al. (1996) 42 vs. 37 CMI (100–250 mg) vs. FLV CMI=FLV
(100–250 mg) FLV=CMI
Milanfranchi et al. (1997) 13 vs. 13 CMI (50–300 mg) vs. FLV CMI=FLV
(50–300 mg) FLV=CMI
Rouillon (1998) 105 vs. 112 CMI (150–300 mg) vs. FLV CMI=FLV FLV>CMI
(150–300 mg)
Paroxetine (PAR)
Zohar and Judge (1996) 99 vs. 201 CMI (50–250 mg) vs. PAR CMI>Placebo PAR>CMI
vs. 99 (20–60 mg) vs. Placebo PAR>Placebo
Sertraline (SER)
Bisserbe et al. (1997) 82 vs. 86 CMI (50–200 mg) vs. SER
(50–200 mg)
SER=CMI SER>CMI
Citalopram (CIT)
Pidrman and Tuma (1998) 24 CIT vs. CMI CIT=CMI CIT=CMI
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producing more weight gain than sertraline and
ﬂuoxetine.
The concept of a ‘gold-standard’ drug for OCD is,
perhaps, misleading. According to YBOCS analyses,
SSRIs appear equally eﬀective at relieving obsessional
thoughts and compulsive rituals. Their improved
safety and tolerability oﬀer considerable beneﬁts for
the long-term treatment of OCD, and indicate that
the SSRIs should usually be considered the treatments
of choice, with clomipramine reserved for those
who cannot tolerate or who have failed to respond to
them.
Expert consensus guidelines for OCD
Expert consensus has a role in complementing and
supplementing empirical evidence. By synthesizing
combined views on best practice, a broader range of
pertinent clinical questions can be addressed. More-
over, such opinions reﬂect experience with a range of
cases and not just the highly selected groups that
meet study criteria. The Expert Consensus Panel for
OCD (March et al., 1997) comprised 65–100 world-
wide experts and the guidelines present speciﬁc
judgements on a comprehensive range of issues relat-
ing to pharmacological and psychological treatments.
The guidelines recommended initial treatment either
with cognitive behaviour therapy (CBT) alone or in
conjunction with an SRI.# Although the guidelines
did not distinguish between clomipramine and
SSRIs, improved tolerability of the latter was acknowl-
edged. Combined CBT and medication was preferred
by experts in terms of speed, eﬃcacy, durability, tol-
erability and acceptability, and was thought the best
approach for most patients. Inclusion of medication
should depend on illness severity and age. More
recently a smaller group of members of the World
Council on Anxiety met to agree recommendations
for long-term treatment (Greist et al., 2003).
What is the most eﬀective dose?
Traditionally, OCD has been thought to require higher
doses of medication than depression and anxiety.
Head-to-head studies comparing diﬀerent ﬁxed doses
of active drug with placebo are needed to examine
this issue. Clomipramine has not been tested in this
way. Whereas the single-dose studies showed eﬃcacy
for relatively low ﬁxed daily doses (75 and 125 mg)
compared to placebo, most studies used ﬂexible
doses titrated towards the upper end of the range
(200–300 mg/d). Similarly, ﬂuvoxamine was found
to be eﬀective in doses ranging from 150–300 mg/d.
Fluoxetine, paroxetine and sertraline have each
been investigated in a series of multiple ﬁxed doses
(Table 3). In the case of paroxetine, a positive dose–
response relationship was clearly demonstrated; in
two studies a 40-mg and 60-mg dose showed eﬃcacy
while a 20-mg dose did not (Hollander et al., 2003b;
Wheadon et al., 1993). Similar results are seen for
ﬂuoxetine: whereas all three ﬁxed doses (20, 40,
60 mg/d) were eﬀective, the greatest beneﬁt was
seen in patients receiving the highest dose, although
Table 3. Placebo-controlled comparator studies of ﬁxed-doses of SSRI
Drug and studies Fixed dose n Duration
Positive
dose–response
relationship?
Fluoxetine
Montgomery et al. (1993) 20/40/60 mg 214 8 wk Yesa
Tollefson et al. (1994) 20/40/60 mg 355 13 wk No
Sertraline
Greist et al. (1995b) 50/100/200 mg 324 12 wk No
Paroxetine
Wheadon et al. (1993) 20/40/60 mg 348 12 wk Yes
Hollander et al. (2003b) 20/40/60 mg 348 12 wk Yes
Citalopram
Montgomery et al. (2001) 20/40/60 mg 352 12 wk No
aMarginally signiﬁcant beneﬁt for medium and higher doses on primary analysis
(total YBOCS, p=0.059); signiﬁcant on ‘responder’ analysis (p<0.05).
#Available evidence suggests that exposure therapy is associated
with similar rates of improvement as pharmacotherapy, and that
combining the two forms of treatment is beneﬁcial, although properly
controlled head-to-head studies have not been performed. A review of
behaviour therapy is beyond the scope of this paper.
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this did not reach statistical signiﬁcance. Adverse
eﬀects appeared to be dose related, with no diﬀerences
between 20-mg and placebo groups, compared to
18.5% early withdrawal in the 60-mg group (Tollefson
et al., 1994). A meta-analysis of the contemporaneous
grouped data showed that the 60-mg dose was
signiﬁcantly more eﬀective than 20 mg (Wood et al.,
1993). A smaller ﬁxed dose comparison of 20, 40 and
60 mg ﬂuoxetine produced clearer ﬁndings. In this
study the 40- and 60-mg doses were eﬀective, but
the 20-mg dose was not (Montgomery et al., 1993).
The existence of a dose–response relationship is less
clear-cut in the case of sertraline and citalopram. In
a multiple ﬁxed-dose study of sertraline (Greist et al.,
1995b), the 50- and 200-mg doses were superior to
placebo, whereas the 100-mg dose was not, possibly
because of increased withdrawal rates in the 100-mg
group. A smaller study (Ushijima et al., 1997) sug-
gested that a dose–response relationship exists for
sertraline as well. In the ﬁxed-dose study of citalo-
pram (Montgomery et al., 2001), a numerical advan-
tage was seen for higher dose-levels, and a signiﬁcant
reduction in baseline YBOCS score was seen from
week 3 in the 60-mg group, compared to weeks 7–12
in the other two groups. However, these diﬀerences
did not reach statistical signiﬁcance.
These mixed results suggest that higher doses (e.g.
60 mg paroxetine, ﬂuoxetine, citalopram; 200 mg
sertraline) produce better anti-obsessional eﬃcacy.
Controlled studies demonstrate eﬃcacy and toler-
ability for doses as high as 80 mg ﬂuoxetine (Jenike
et al., 1997; Leibowitz et al., 2002) and 300 mg clomi-
pramine (de Veaugh-Geiss et al., 1989). The expert
guidelines advocate treatment at moderate dose-levels
in most cases, only titrating upwards to the maximum
after a period of assessment.
Strategies for dose titration in OCD
Acute studies of SRIs show a slow, gradual treatment
eﬀect and, unlike panic disorder, exacerbation of
anxiety is rare in the ﬁrst days of treatment. Improve-
ments can take several weeks to become established,
irrespective of dose, and patients should be warned
about this from the outset. Individuals with OCD are
notoriously poor at recognizing their own improve-
ments, and it is useful to enlist the help of informants
to report early signs of improvement. Observer-rated
scales may also detect small improvements in a clinical
setting, although in some cases observable beneﬁts
may not appear for several months. These cases can be
extremely challenging, with pressure on the clinician
to change treatments or escalate doses prematurely.
Given the dose–response data, there are clear grounds
for titrating doses upwards, but the clinician needs to
strike a delicate balance between speed of increase
and tolerability. Fast upwards titration may produce
earlier responses, but the long-term beneﬁts of this
approach are unclear. A single-blind study compared
rapid dose escalation with sertraline to 150 mg over
5 d, with slower dose escalation over 15 d, and found
a signiﬁcant diﬀerence in favour of the rapid titration
group at weeks 4 and 6, but this advantage dis-
appeared thereafter (Bogetto et al., 2002). The study
was too small to discern diﬀerences in tolerability.
In another study, pulse loading with intravenous
clomipramine produced a large and rapid decrease
in obsessive symptoms, but oral pulse loading did
not, and the early advantages were not sustained
over treatment (Koran et al., 1997). The arguments
for slower dose increases may be more persuasive,
particularly in children and the elderly. Early SSRI-
related adverse eﬀects such as nausea and agitation
can be ameliorated by slowly titrating upwards over
weeks and months. Longer-term side-eﬀects such as
sleep disturbance and headache are also dose-related,
and need to be monitored. Sexual dysfunction is
a common cause of drug discontinuation, and, if
necessary, strategies such as dose reduction, short
drug-holidays or use of drugs with restorative potency
(e.g. nefazodone, viagra, mianserin; Aizenberg et al.,
1999) can be considered in stable cases.
The expert guidelines recommend continuing treat-
ment at average dose levels for 4–8 wk. If there are
no signs of improvement at that point, they suggest
proceeding to the maximum licensed dose. In the
case of partial improvement, the guidelines suggest
waiting longer for the eﬀect to increase (5–9 wk) before
titrating the dose upwards. When at the highest dose
it is best to continue for at least 3 months (in some
cases longer periods are required) to allow the treat-
ment eﬀect time to develop.
SRIs are the treatment of choice in comorbid
depression
Moderate levels of depression do not interfere with
the anti-obsessional response (Zohar and Judge, 1996).
However, comorbid depression has received relatively
little attention because most studies have excluded
depressed individuals. Clomipramine, ﬂuvoxamine
and sertraline have been compared with desipramine
in groups where comorbid depression was included.
In the study by Hoehn-Saric et al. (2000) patients
were speciﬁcally selected for the presence of signiﬁ-
cant depression. In general, comorbid depression
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responded in parallel with OCD, and shared its
characteristic selectivity for the serotonergic drug. It
is unusual for an antidepressant like desipramine to
show such a poor response. These results suggest that
the depression is either integral or secondary to OCD,
and imply that depressed patients with OCD should
be treated with an SRI. OCD frequently co-occurs with
bipolar disorder, with lifetime comorbidity as high
as 30% (Kruger et al., 1995). This presents a challenge
since SRIs can be associated with a switch to mania.
SSRIs are less risky than clomipramine in this respect,
and judicious administration of mood-stabilizing
medication together with caution in dose escalation
are advisable (Kaplan and Hollander, 2003). Unlike
drugs, studies of behaviour therapy suggest that
moderately high levels of baseline depression ad-
versely aﬀect the treatment outcome (Kejsers et al.,
1994). This disadvantage may be neutralized by aug-
menting psychotherapy with a SSRI (Hohagen et al.,
1998), although studies investigating this have been
unable to disentangle the anti-obsessional eﬀects of
medication from those of behavioural interventions.
These ﬁndings suggest that the ﬁrst-line treatment
for depressed patients with OCD should be a SSRI.
Other treatments
Preliminary reports hinting at beneﬁts for a variety of
agents acting on serotonin, such as mianserin and
mirtazapine (Koran et al., 2001a), and the serotonin
precursor L-tryptophan (Montgomery et al., 1992),
are of theoretical value. There has been particular
interest in the role of venlafaxine in OCD which, in
low doses, acts mainly as a SSRI, but in doses exceed-
ing 225 mg combines this activity with norepinephrine
reuptake inhibition. A small, placebo-controlled trial
(n=30) failed to separate venlafaxine from placebo
(Yaryura-Tobias andNeziroglu, 1994).Venlafaxinewas
also compared to paroxetine in a non-placebo, double-
blind study of non-depressed OCD cases (Denys et al.,
2003a) where 75 individuals received paroxetine
(60 mg) and 75 venlafaxine (300 mg). Both treatments
appeared equally eﬀective at reducing YBOCS scores.
An evaluation of quality-of-life measures from the
study also showed equivalent improvements (Tenney
et al., 2003). A smaller single-blind study comparing
venlafaxine with clomipramine also failed to reach
signiﬁcance, although 42.6% (20/47) of the clomipr-
amine group were responders compared to 34.6%
(9/26) on venlafaxine on the ITT analysis (Albert
et al., 2002). Further evaluation of the relative eﬃcacy
and tolerability of venlafaxine is warranted.
How long should treatment be continued?
OCD is a long-term illness and we need to know if
acute treatments maintain eﬃcacy in the longer term.
In comparison to the evidence base for acute treatment
of OCD, the long-term outcome is less clear. Evidence
for long-term eﬃcacy can be derived from a variety of
sources. Some investigators have followed treatment
responders from acute-phase studies on uncontrolled
SRIs for up to 2 yr, without tolerance developing.
The study by Wagner et al. (1999), reported ongoing
eﬃcacy for open-label sertraline up to 1 yr in a large
cohort of children and adolescents. Evidence from
controlled studies is more convincing (Table 4).
Cottraux et al. (1990) reported a signiﬁcant beneﬁt for
ﬂuvoxamine over placebo, but only for depressive
symptoms. Katz et al. (1990) randomized patients
to either clomipramine (100–300 mg) or placebo for
10 wk, after which they entered 124 responders into a
52-wk double-blind extension period. Clomipramine’s
superiority over placebo was sustained over the
Table 4. Placebo-controlled studies of long-term treatments for patients with OCD
Study Active treatment n
Duration
(wk) Outcome
Cottraux et al. (1990) Fluvoxamine+ 50 8 Fluvoxamine superior to placebo in follow-up phase,
exposurea 44 24 but only for depression
37 48
Katz et al. (1990) Clomipramineb 110 (10+) 52 Superiority of clomipramine sustained in follow-up phase
Tollefson et al. (1994) Fluoxetineb 76 (13+) 24 Improvement on all doses, 60 mg signiﬁcant above others
Greist et al. (1995a) Sertralineb 118 (12+) 40 Signiﬁcant additional improvements in OCD symptoms
for sertraline
a Extended double-blind study.
b Double-blind continuation in acute phase (rwk) responders.
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extension phase, to the extent that OCD was no longer
compromising the lives of half the clomipramine
group. However, a high incidence of adverse eﬀects
in the clomipramine group resulted in 23% with-
drawing early.
Tollefson et al. (1994) followed up 76 responders
from the 13-wk multiple ﬁxed-dose, placebo-con-
trolled ﬂuoxetine study on their ascribed treatment
up to 24 wk. Patients on all doses of ﬂuoxetine (20, 40,
60 mg) continued to improve, with further signiﬁcant
improvements evident for the 60-mg group only. Only
6% of ﬂuoxetine-treated individuals discontinued
due to side-eﬀects. In the large extension study by
Greist et al. (1995a), 118 patients who had responded
to 12-wk treatment with sertraline or placebo con-
tinued under double-blind conditions for 40 wk. The
patients maintained their improvements as long as
they remained on sertraline. Compliance was good:
only 13% patients dropped out of treatment prema-
turely during the extension phase. Of these, one third
blamed side-eﬀects and two thirds blamed unsatis-
factory clinical response. Side-eﬀects improved over
time, and there were no statistically signiﬁcant diﬀer-
ences between sertraline and placebo in vital signs or
laboratory abnormalities. Fifty-nine completers were
followed up for a further year on open-label sertraline,
and showed signiﬁcant additional improvements in
OCD symptoms over the course of the second year,
with a reduced incidence of side-eﬀects compared to
the earlier study (Rasmussen et al., 1997).
How long should treatment continue?
One way of tackling this question is to explore
whether continuation of pharmacotherapy provides
ongoing protection against deterioration. A promising
technique involves taking patients who have re-
sponded to active drug and comparing their ‘relapse’
rates following randomization to either continuous
drug treatment or drug discontinuation. Planning and
interpretation of drug-discontinuation studies is not
always straightforward. There is still debate about
the deﬁnition of a meaningful clinical response and
the concept of ‘relapse’ has been even more diﬃcult
to apply to an illness that runs a chronic course
and shows partial response to long-term treatment.
Indeed, the lack of agreed deﬁnitions for ‘relapse’
makes inter-study comparison diﬃcult. Criteria such
as o50% worsening of post-baseline YBOCS im-
provement, 5-point worsening of YBOCS, YBOCS total
score of o19, CGI-I scores of ‘much’ or ‘very much
worse’ have been proposed. Some studies have
erred towards imposing too stringent qualiﬁcations,
requiring more than two criteria to be present at any
one time (Romano et al., 2001), or requiring criteria
to persist over several visits (Koran et al., 2002). This
has compromised the sensitivity to detect outcome
diﬀerences. In addition, studies need to diﬀerentiate
between early ‘withdrawal eﬀects’ occurring soon
after drug termination, and a more gradual re-
emergence of OCD. Withdrawal eﬀects are related
to the pharmacological properties of the compound,
and are believed to complicate clomipramine and
paroxetine more than ﬂuoxetine (Rosenbaum et al.,
1998).
A series of controlled studies has shown that dis-
continuation of treatment is positively associated
with symptomatic relapse, irrespective of treatment
duration (up to 2 yr) (Table 5). For most agents,
symptoms re-emerged within only a few weeks of
stopping medication. The earlier clomipramine
studies showed relatively high, early relapse rates,
possibly related to stronger withdrawal symptoms.
For example, in the discontinuation study by Pato
et al. (1988), 16 out of 18 patients exhibiting sustained
improvements on clomipramine showed substantial
worsening of symptoms within 4 wk of crossing
over to placebo. The re-emergence of symptoms was
gradual and progressive and unrelated to duration
of clomipramine pre-treatment, which exceeded 2 yr
in some cases. In this study, reinstatement of clomi-
pramine resulted in improvement to a level close to
pre-discontinuation, although other authors have re-
ported less favourable results. Similarly, in the study
by Leonard et al. (1988), 89% patients relapsed within
2 months of switching to placebo.
In the relapse-prevention study by Romano et al.
(2001), responders to 20-wk ﬁxed-dose ﬂuoxetine
were randomized to continuation or placebo and
followed up for a year. Relapses were stringently de-
ﬁned, and 38% relapsed over 12 months following
double-blind discontinuation. Patients remaining on
the highest dose (60 mg) showed signiﬁcantly lower
relapse rates (17.5%), but the study still did not dis-
criminate between continuation and switching. In
spite of its larger size and longer duration, the study
by Koran et al. (2002) was also unable to demonstrate
a signiﬁcant advantage for sertraline on the a-priori
criterion for preventing relapse; in this case almost
certainly because the criterion for relapse was too
strictly deﬁned. However, those remaining on sertra-
line showed signiﬁcantly fewer ‘drop-outs due to
relapse or insuﬃcient clinical response’ (9% vs. 24%
on placebo) and ‘acute exacerbation of symptoms’
(12% vs. 25% on placebo), and ongoing sertraline
was associated with continued improvement in
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YBOCS, NIMH-OC, CGI scores and quality-of-life
measures.
A discontinuation study investigating adults who
had responded to 6 months’ paroxetine (Dunbar et al.,
1995) was presented at an international meeting but
has not been published. Results showed that those
who continued on paroxetine suﬀered signiﬁcantly
fewer relapses during the next 36 wk than those
who switched to placebo. Approximately 10% of
paroxetine-treated patients had a full relapse, com-
pared to 18% on placebo. The ITT analysis showed
a signiﬁcantly shorter time-to-relapse on placebo.
YBOCS scores were maintained or slightly improved
under paroxetine, but deteriorated under placebo.
A more recent large-scale study of paroxetine by
Hollander et al. (2003b) looked at 105 responders to
6 months’ treatment and demonstrated a signiﬁ-
cantly better outcome for those remaining on the
active drug over the 6-month, double-blind discon-
tinuation phase: 59% of patients randomized to
placebo relapsed, compared to 38% on paroxetine
(20–60 mg), with paroxetine being well tolerated
across the dose range. Geller et al. (2003b) investigated
paroxetine in children and adolescents, of whom
more than half had at least one comorbid illness, using
a relapse-prevention design. After 16-wk open-label
paroxetine, 193 responders were randomized to a
further 16-wk double-blind treatment on paroxetine
or placebo. The overall relapse rate was not signiﬁ-
cantly higher in the placebo than the paroxetine group
(43.9% vs. 34.7%), possibly because the duration of
follow-up was too short. Post-hoc analyses showed
a signiﬁcantly greater relapse rate for patients with
comorbid disorders than those with uncomplicated
OCD randomized to placebo, but this did not apply
under paroxetine. The authors argued that patients
with comorbidity are at increased risk of relapse fol-
lowing discontinuation and that studies which too
rigorously exclude comorbid disorders may under-
estimate relapse rates in clinical samples of OCD.
It is diﬃcult to draw strong conclusions from these
mixed ﬁndings. We may surmise that medication
probably confers protection against relapse, as long
as it is continued. The Expert Consensus Guidelines
(March et al., 1997) recommended pharmacotherapy
maintenance for a minimum of 3–6 months after
Table 5. Double-blind discontinuation studies of relapse prevention in OCD
Study Drug
Duration
prior drug
treatment
No. in
discontinuation
phase
Follow-up after
discontinuation
(wk) Outcome
Yaryura-Tobias et al.
(1976)
Clomipramine 4 or 6 wk 13 1 Worsening of OCD on placebo
Flament et al. (1985)a Clomipramine 5 wk 19 5 Worsening of OCD on placebo
Pato et al. (1988) Clomipramine 5–27 months 18 7 94.4% relapsed on placebo
Leonard et al. (1988)b Clomipramine 17 months 21 5 89% relapsed on placebo
Dunbar et al. (1995)c Paroxetine 9 months 104 36 Relapse rate on
placebo>paroxetine
Romano et al. (2001)c Fluoxetine 20 wk 71 52 Relapse rate on placebo=
pooled ﬂuoxetine
Relapse rate on
placebo>ﬂuoxetine 60 mg
Koran et al. (2002)c Sertraline 52 wk 223 28 Relapse rate on
placebo=sertraline
Acute exacerbation of OCD on
placebo>sertraline
Drop-outs due to relapse on
placebo>sertraline
Geller et al. (2003b)b Paroxetine 16 wk 193 16 Relapse rate on placebo=
paroxetine
Hollander et al. (2003b)c Paroxetine 12 wk 105 36 Relapse rate on placebo>
paroxetine
a In children.
b In children and adolescents.
c Survival analysis performed.
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acute treatment, reserving long-term treatment only
for subsequent relapses. However, it was also noted
that much longer periods, exceeding 2 yr, were
usually needed, and that lifelong treatment was
warranted after 2–4 relapses. More recent guidelines
(Greist et al., 2003) have more strongly emphasized
the importance of long-term treatment from the
outset and recommended continuation of pharmaco-
therapy for a minimum of 1–2 yr in treatment-
responsive individuals. Discontinuation, if necessary,
should be gradual to minimize discontinuation eﬀects,
and patients should be warned to look out for early
signs of relapse whereupon reinstatement of pharma-
cotherapy may achieve the same level of improvement
as before, although this cannot be guaranteed (Ravizza
et al., 1998). Until clear predictors relating to relapse
are available, lifelong medication may be the best
option for most cases.
What is the best dose for long-term treatment?
There is little evidence supporting dose reduction
in long-term treatment, apart from one small study
where lowering the dose of clomipramine and ﬂuvox-
amine did not aﬀect relapse rates (Mundo et al.,
1997b). Results from Romano et al.’s (2001) study, in
which a 60-mg dose of ﬂuoxetine appeared the most
eﬀective over the 24-wk extension phase, support
continuation of treatment at higher dose levels. On the
basis of the limited data available, most experts rec-
ommend continuing treatment at the eﬀective dose,
and the adage ‘the dose that gets you well, keeps
you well ’ probably applies.
Preferred treatments after poor response to
ﬁrst-line drugs
Predictors of treatment response
Although most patients experience substantial im-
provements, for many the treatment response is not
complete. In approx. 30% cases residual symptoms
remain in spite of prolonged treatment with SRIs. The
problem of ‘partial responders’ is an area that has
received inadequate controlled investigation and
which is bedevilled by the lack of universally accepted
deﬁnitions. Pallanti et al. (2002a) advocated the use
of standardized operational criteria across treatment
trials. Speciﬁcally, they proposed that an improve-
ment ofo35% in baseline YBOCS score, or ‘much’ or
‘very much improved’ on the CGI-I, represented a
meaningful clinical response, while ‘remission’ re-
quired a total YBOCS score of <16. Those showing
between 25% and 35% improvement in YBOCS scores
were considered partial responders. Relapse was de-
ﬁned as a 25% worsening in YBOCS (or a CGI score
of 6), after a period of remission, and the term ‘treat-
ment refractory’ was reserved for those who do not
respond to ‘all available treatments’. Levels of non-
response, according to the numbers of failed treat-
ments, were also deﬁned.
Few studies provide information on response
status, and the literature on pharmacological response
predictors is sparse and inconsistent. Mataix-Cols
et al.’s (1999) factor analysis suggests that adults with
compulsive rituals, early-onset age, longer duration,
chronic course, comorbid tics and personality dis-
orders (especially schizotypal), respond poorly to
clomipramine and SSRIs. Additional analyses of
large databases for clomipramine and ﬂuoxetine
reported better responses for previously SRI-naive
patients, and poorer responses for those with sub-
clinical depression. Patients with an earlier age of
onset responded poorly to clomipramine, but not to
ﬂuoxetine (Ackerman and Greenland, 2002). The more
recent analysis of data from a large trial of citalopram
also reported that patients with a longer duration of
illness or previous SSRI treatment, as well as greater
illness severity, were less likely to respond well to the
active drug (Stein et al., 2001). One small study has
identiﬁed better responses in females (Mundo et al.,
1999) and children with comorbid ADHD, tic disorder
and oppositional deﬁant disorder showed a less
favourable response (Geller et al., 2003b).
Switching SRI, increasing dose or changing mode
of drug delivery
Given the limitations of data supporting alternative
strategies, and the acceptability of switching from
one SSRI to another, this remains the preferred option
for many clinicians. Sometimes, however, it may be
appropriate to persist for longer with a particular SRI
even in patients who show little sign of improvement,
since a delayed response may occur after 6 months
or more. March et al. (1997) recommended changing
the SRI after 8–12 wk on the maximal dose if the
clinical eﬀect was incomplete. They proposed a 40%
chance of responding to a second SRI, and a lesser
response to a third and suggested switching to clomi-
pramine after 2–3 failed trials on SSRIs. An unpub-
lished report by Ravizza et al. (2001) looked at patients
who had failed to respond to at least two trials of SSRIs
other than citalopram. Patients were randomized to
clomipramine, venlafaxine or citalopram for 12 wk
and 14% responded to citalopram, 37.5% to clomi-
pramine and 42% to venlafaxine. A single-blind study
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in 29 cases of SRI-resistant OCD showed encourag-
ing results for venlafaxine (37.5–375 mg) as a mono-
therapy (Hollander et al., 2003c). These results hint
that patients who have failed to respond to two SSRIs
may beneﬁt from switching to an agent with a diﬀer-
ent mode of action.
Results from uncontrolled case studies suggest
that, for some patients, increasing SSRI doses above
formulary limits can procure a better eﬀect (Bejerot
and Bodland, 1998; Byerly et al., 1996). Although
doses of clomipramine up to 300 mg have been
systematically investigated and found to be accept-
able, the risk of seizures and cardiotoxicity associ-
ated with this drug suggest that doses exceeding this
should be generally avoided. Altering the mode of
administration may be considered although this is
not practical in many cases. Intravenous clomipramine
has been shown to be more eﬀective than placebo in
a single, double-blind study investigating refractory
OCD, with 6 out of 29 randomized to clomipramine
classed as responders after 14 daily infusions, com-
pared to none for placebo (Fallon et al., 1998). A posi-
tive open study of 21-d intravenous citalopram has
also been reported (Pallanti et al., 2002b).
Combining SRIs and drugs exerting antidepressant
or anxiolytic properties
If a patient fails to respond to successive SRI trials,
augmented with CBT, the Expert Consensus Guideline
recommends adding another agent to the SRI. The
evidence is acknowledged to be limited, based on
the results of small studies and open case-series
(Table 6). Combining clomipramine with a SSRI has
been proposed for adults or children unresponsive
to, or intolerant of, SRI monotherapy. This strategy
should be approached with caution since the pharma-
cokinetic interactions on the hepatic cytochrome P450
isoenzymes may lead to a build-up of clomipramine
that could be dangerous, and ECG and plasma-level
monitoring is advisable. Positive results have been
reported from small, uncontrolled case series (Szegedi
et al., 1996), although the ﬂuoxetine–clomipramine
combination resulted in ECG changes in some cases.
Pallanti et al. (1999) compared nine treatment-refrac-
tory patients given citalopram+clomipramine with
seven given citalopram alone, in a randomized open-
label trial. They reported a signiﬁcantly larger im-
provement in YBOCS ratings for those given the
combination, all of whom experienced decreases
o35% from baseline. This combination is advan-
tageous in not altering the metabolism of clomipr-
amine, and was well tolerated. No controlled studies
of the co-administration of diﬀerent SSRIs have been
published.
Controlled studies have conﬁrmed the lack of eﬃ-
cacy of lithium augmentation in OCD (McDougle
et al., 1991; Pigott et al., 1991). Similarly, three double-
blind, placebo-controlled studies have demonstrated
that combining buspirone with an SRI is not helpful
(Grady et al., 1993; McDougle et al., 1993; Pigott
et al., 1992a). Clonazepam is a benzodiazepine with
putative eﬀects on serotonin neurotransmission. As
a monotherapy it fails to impact on the core symp-
toms of OCD (Hollander et al., 2003d) although it
may help with associated anxiety. Pigott et al. (1992b)
reported limited eﬃcacy for clonazepam given
together with ﬂuoxetine or clomipramine in a placebo-
controlled study. Pindolol is a beta-blocker which also
acts as an antagonist at pre-synaptic 5-HT1A auto-
receptors. Dannon et al. (2000) demonstrated eﬃcacy
for pindolol when combined with paroxetine in
a double-blind, placebo-controlled study of 14 treat-
ment-resistant cases, but another study combining it
Table 6. Treatment refractory OCD
Double-blind, placebo-controlled pharmacotherapy studies
May be eﬀective
$ Intravenous clomipraminea
$ Adding haloperidolc
$ Adding risperidone
$ Adding quetiapine
$ Adding clonazepamb
Apparently ineﬀective
$ Adding lithium
$ Adding buspirone
$ Adding triiodothyronine (liothyronine)
$ Adding desipramine
$ Adding inositol
Promising treatments warranting controlled study
$ Higher-dose SSRI monotherapy
$ Combined SSRI–clomipramine treatment
$ Extended SRI therapy
$ Adding olanzapine
$ Adding amisulpride
$ Intravenous citalopram
$ Tryptans that enter the CNS, e.g. zolmitriptan
$ Immunoglobulins and plasmapharesis
$ Deep brain stimulation
$ Neurosurgery (gamma knife surgery)
a Remains investigational in many countries.
b Small numbers and improvement not evident on all OCD
rating scales.
c Primarily in ‘tic-related’ OCD.
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with ﬂuvoxamine did not (Mundo et al., 1998). Blier
and Bergeron (1996) found a beneﬁcial eﬀect for
pindolol only when L-tryptophan was openly added
to the combination. The limitations of adding drugs
acting on serotonin led investigators to re-examine
the role of noradrenergic agents in resistant OCD. Barr
et al. (1997) investigated the addition of desipramine
to 20 patients who had failed SSRI monotherapy, in
a double-blind, placebo-controlled study, and found
no added beneﬁt.
Combining SRIs and drugs with antipsychotic
properties
No positive studies of antipsychotic monotherapy
in OCD meet today’s standards, and OCD is not rec-
ognized as responding to these drugs individually.
McDougle et al. (1990) reported a beneﬁt from adding
open-label pimozide (6.5 mg) in 17 patients unrespon-
sive to ﬂuvoxamine. Patients with comorbid chronic
tics or schizotypal disorder were most responsive. A
subsequent double-blind, placebo-controlled study
by the same author demonstrated a signiﬁcant YBOCS
improvement for low-dose haloperidol (6.2 mg) added
to ﬂuvoxamine. Eleven out of 17 patients receiving
the active drug achieved ‘responder’ status by as early
as 4 wk, compared to none on placebo. Again, a pref-
erential response was seen in patients with comorbid
tics (McDougle et al., 1994). Antipsychotics such as
haloperidol and sulpiride are ﬁrst-line treatments
for Tourette’s syndrome, so this ﬁnding supports a
theoretical link between these disorders. This com-
bination increases the side-eﬀect burden, includ-
ing extra-pyramidal eﬀects. It is therefore wise to
start treatment with very low doses, and increase
cautiously subject to tolerability (e.g. 0.25–0.5 mg halo-
peridol, titrated slowly to 2–4 mg; McDougle and
Walsh, 2001).
Newer second-generation antipsychotics, that
modulate serotonin and dopamine neurotransmission,
also oﬀer promise and have a lower risk for side-
eﬀects. Positive reports from open case-series were
conﬁrmed by McDougle et al. (2000) in the ﬁrst
reported double-blind, placebo-controlled study
showing eﬃcacy for risperidone augmentation in 36
patients unresponsive to 12 wk on an SRI. Risperidone
(2.2 mg) was superior to placebo in reducing YBOCS
scores as well as anxiety and depression, was well
tolerated and there was no diﬀerence between those
with and without comorbid tics or schizotypy. A
smaller double-blind study by Hollander et al. (2003e)
examined patients failing to respond to at least two
trials of SRIs. Four out of 16 patients randomized to
risperidone (0.5–3 mg) turned out to be responders,
deﬁned as a CGI-I score of 1 or 2 and a YBOCS de-
crease of o25% at the 8-wk end-point, compared to
none of the six patients randomized to placebo.
Quetiapine has also been the subject of recent con-
trolled investigation. There have been contradictory
results from open (Sevincok and Topuz, 2003) and
single-blind studies (Atmaca et al., 2002). However,
the recent double-blind, placebo controlled study by
Denys et al. (2003b), published in abstract form,
showed clear evidence of eﬃcacy for 8-wk quetiapine
(<300 mg) augmentation in 20 SRI-refractory patients,
showing a mean decrease of 30% on baseline YBOCS,
compared to 20 controls who showed only 6% im-
provement. Encouraging results from a small number
of open-label studies of olanzapine (D’Amico et al.,
2003) and an open-label study of amisulpride (Metin
et al., 2003) suggest that these drugs may also be
helpful, and further investigation is underway. The
results for clozapine have been less encouraging
(McDougle et al., 1995). Some authors report emerg-
ent obsessions during treatment with atypical anti-
psychotics, which may be related to their mixed
receptor antagonist properties. Altogether, these
results favour the use of second-generation anti-
psychotics as the ﬁrst-line strategy for augmentation
in resistant OCD. It remains uncertain as to how long
patients need to remain on augmented treatment.
A small retrospective study by Maina et al. (2003b)
showed that the vast majority of patients who had
responded to the addition of an antipsychotic to their
SRI, subsequently relapsed when the antipsychotic
was withdrawn.
Other strategies for refractory OCD
Inositol (18 g/d) is an experimental compound that
acts through intracellular messenger systems. It was
thought to have mild anti-obsessional eﬃcacy but
results from a placebo-controlled augmentation study
by Fux et al. (1999) refute this. Sumatriptan is a 5-
HT1D agonist used to treat migraine. A small open
case-series suggested improvement over 4-wk treat-
ment but, in a double-blind, placebo-controlled study
of 10 patients, 5-d treatment was associated with a
worsening of OCD (Koran et al., 2001b). Drugs that
alter immune system response may have a role
in refractory OCD. For example, syndromes of
sudden-onset OCD following childhood streptococcal
infections are recognized, and these may respond to
plasmapharesis and intravenous immunoglobulin
(Perlmutter et al., 1999). Preliminary reports that
repetitive trans-cranial magnetic stimulation may
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reduce compulsions (Greenberg et al., 1997) have not
been substantiated in treatment studies. Neither is
ECT considered eﬀective, although it may help relieve
severe comorbid depression. Stereotactic neurosur-
gery should be viewed as a last option. Techniques
such as cingulotomy and capsulotomy have produced
improvements in some intransigent cases, but the
absence of controlled trial data, including long-term
follow-up on adverse eﬀects, is discouraging. Deep
brain stimulation involves less intra-cerebral neuronal
damage and holds promise for future investigation.
Conclusions
An extensive evidence base now exists for the pharma-
cological management of OCD. First-line treatment
with a SSRI is uncontroversial, with improvements
being sustained over time, although response is often
incomplete with many individuals failing to respond
adequately. Treatment-resistant OCD is now receiving
systematic evaluation: augmentation with second-
generation antipsychotic agents appears a promising
strategy and other techniques for resistant cases are
under evaluation. Important questions requiring fur-
ther investigation include identiﬁcation of clinically
relevant predictors relating to treatment–response and
relapse, the clariﬁcation of optimal duration of treat-
ment and the evaluation of anti-obsessional treatment
in comorbid disorders such as schizophrenia with
OCD. Agreed deﬁnitions for response, relapse, resist-
ance and refractoriness will improve research in this
area.
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